Board of Directors

Elected to the Board of Directors in 2017 and Chair of the Board since 2020. Stig is regarded as an independent board member.

Special competencies

Stig has more than 35 years of strategic, commercial and leadership expertise from the life science industry, holding senior positions at H. Lundbeck and Ciba-Geigy.

Current positions

Chairman of the Board of Directors and member of the Board in several private and publicly listed  biotechnology companies, including Dizlin AB, StemMedical and SSI Diagnostica. In addition, Stig is Operating Partner in the private equity fund Catacap.

Education

Stig holds an M.Sc. in Economics from Aalborg University, Denmark.

Nationality

Danish

Andrew J. Oakley was elected to the Board of Directors in 2019 and is regarded as an independent board member.

Special competencies

Andrew is a global executive with more than 30 years of financial and capital markets experience, holding positions as Chief Financial Officer of Actelion, Vectura PLC, Sosei Group Corporation, Autolus Therapeutics PLC and Theolytics Ltd.

Current positions

Andrew currently serves as Chief Financial Officer of TargImmune Therapeutics AG, and is a board member of Novaremed AG, Virometix AG and Onconetix Inc. (ONCO).

Education

Andrew holds a Bachelor of Economics degree from Macquarie University and an MBA from London Business School, United Kingdom. Andrew has been a member of the Australian Institute of Chartered Accountants since 1987.

Nationality

Australian

Peter Kristensen was elected to the Board of Directors in 2024 and is regarded as an independent board member.

Special competencies

Peter has more than 30 years of drug development and regulatory experience from Novo Nordisk, as Senior External Advisor with McKinsey & Co and as an independent consultant. At Novo Nordisk, Peter started as a research scientist, headed the development of Victoza (liraglutide) and was for 10+ years Senior Vice President of drug development, project management and global clinical operations.

Current positions

Independent consultant.

Education

Peter has a Medical Degree and a Medical Doctorate from University of Copenhagen, an E*MBA from SIMI (today part of CBS Executive) and is a member of the Danish Academy of Technical Sciences.

Nationality

Danish

Member of the Board, and not considered independent due to being Co-CEO as well as co-founder and major shareholder of UNION.

Special competencies

Extensive leadership and strategic development experience from founding and building companies in the life science industry. Before going into biotech, Rasmus worked in investment banks and in management consulting.

Current positions

Rasmus is the Co-CEO of UNION and co-founder of multiple companies. He is also board member at UTILITY Therapeutics.

Education

Rasmus holds a Ph.D. in Entrepreneurship from Copenhagen Business School and executive education from Harvard Business School.

Nationality

Danish

Member of the Board, and not considered independent due to being CSO as well as co-founder and shareholder of UNION.

Special competencies

Extensive research and development experience working within fields of drug development, industrial biotechnology and microbiome research. Morten has published more than 100 scientific publications and is an inventor of several issued patents.

Current positions

Morten is the Chief Scientific Officer of UNION and holds the position as Professor and Scientific Director at the Technical University
of Denmark. Morten is member of the board in Novonesis, Clinical-Microbiomics, SNIPR biome and UTILITY therapeutics.

Education

Morten holds a M.Sc. in Physics from University of Copenhagen and a Ph.D. in Biophysics from Harvard University from the laboratory of Professor George Church.

Nationality

Danish